Virtu Financial LLC Takes $92,000 Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Virtu Financial LLC bought a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) in the 3rd quarter, Holdings Channel.com reports. The firm bought 19,875 shares of the company’s stock, valued at approximately $92,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TLSI. Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. Vestcor Inc purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at about $108,000. MSD Partners L.P. bought a new stake in TriSalus Life Sciences in the 3rd quarter worth approximately $184,000. Walleye Capital LLC purchased a new stake in TriSalus Life Sciences in the third quarter worth approximately $66,000. Finally, Duquesne Family Office LLC grew its position in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after acquiring an additional 110,966 shares during the last quarter. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at TriSalus Life Sciences

In related news, major shareholder Equity Ab Frankenius purchased 62,972 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the acquisition, the insider now directly owns 6,230,748 shares in the company, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired a total of 70,012 shares of company stock worth $281,235 in the last 90 days. Company insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Trading Down 4.3 %

Shares of NASDAQ:TLSI opened at $3.60 on Friday. The company has a 50-day moving average price of $4.14 and a 200-day moving average price of $4.96. The company has a market cap of $109.77 million, a price-to-earnings ratio of -1.45 and a beta of 0.56. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $10.42.

Wall Street Analysts Forecast Growth

TLSI has been the subject of a number of recent research reports. Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a report on Tuesday. They issued an “overweight” rating and a $10.00 price objective for the company. Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target for the company. Canaccord Genuity Group cut their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Finally, Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Buy” and a consensus target price of $11.79.

TriSalus Life Sciences Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.